ArticleNature2020
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
Abstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 604 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
604citing papers in PubMed, 2 pooled it
43.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
604 citing papers in PubMed, 2 syntheses or guidelines pooled it, 973 citations in OpenAlex.
- Comparative efficacy, immune response, and safety of mRNA versus dendritic cell vaccines in solid tumors: a systematic review and meta-analysis.Journal of translational medicine · 2026Pooled it
- Global hotspots and trends in pre-metastatic niche research: a bibliometric analysis(2005-2024).Frontiers in immunology · 2025Pooled it
- Twenty-year survival outcomes after multipeptide vaccination for resected high-risk melanoma: A post-hoc analysis of a randomized clinical trial.International journal of cancer · 2025Trial
- TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study.Nature communications · 2025Trial
- Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers.Nature communications · 2025Trial
- Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy.Oncoimmunology · 2026Article
- Modular mRNA cocktail enables synergistic activation of antigen-specific T cells for cancer immunotherapy.Oncoimmunology · 2026Article
- Early neutrophil infiltration promotes TRIMELVax-induced antitumor immunity by linking local inflammation to tumor control.Oncoimmunology · 2026Article
- Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8Molecular therapy. Nucleic acids · 2026Article
- Engineered nanovaccines for prophylactic and therapeutic immunotherapy against cancer and infectious disease.Human vaccines & immunotherapeutics · 2026Review
- A bottleneck-first evaluation of antigen delivery platforms for therapeutic cancer vaccines.Materials today. Bio · 2026Review
- Current landscape of clinical trials for mRNA-based therapeutics.Human vaccines & immunotherapeutics · 2026Review
- Cancer nanomedicine and RNA/Lipid nanoparticle platforms in oncology: developmental evolution, translational barriers, and precision-therapy opportunities.Journal of the Egyptian National Cancer Institute · 2026Review
- Mechanistic insights and therapeutic implications of mitoxyperilysis: a spatially gated mitochondria-dependent lytic cell death.Apoptosis : an international journal on programmed cell death · 2026Review
- Bioengineering strategies for improving the immunogenicity of mRNA vaccines.Signal transduction and targeted therapy · 2026Review
- Localized immunotherapy via dissolving microneedles for the prevention of breast cancer recurrence.Drug delivery and translational research · 2026Review
- Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.MedScience · 2026Review
- Preclinical study of an optimized AAV cancer vaccine in a spontaneous canine model of oral melanoma.Molecular therapy. Oncology · 2026Article
- Therapeutic cancer vaccines: development, challenges, and future perspectives.Acta pharmacologica Sinica · 2026Review
- Breast cancer prevention by prophylactic Lalba mRNA-LNP vaccination.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
544 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
41 authors at 5 institutions in 1 country.
Ugur SahinBioNTech, Mainz, Germany. ugur.sahin@biontech.de.ORCID http://orcid.org/0000-0003-0363-1564
Petra OehmBioNTech, Mainz, Germany.ORCID http://orcid.org/0000-0002-1086-2726
Evelyna DerhovanessianBioNTech, Mainz, Germany.
Robert A JabulowskyBioNTech, Mainz, Germany.
Mathias VormehrBioNTech, Mainz, Germany.ORCID http://orcid.org/0000-0001-7788-3380
Maike GoldBioNTech, Mainz, Germany.
Daniel MaurusBioNTech, Mainz, Germany.
Doreen Schwarck-KokarakisBioNTech, Mainz, Germany.
Andreas N KuhnBioNTech, Mainz, Germany.
Tana OmokokoBioNTech, Mainz, Germany.
Lena M KranzBioNTech, Mainz, Germany.
Mustafa DikenBioNTech, Mainz, Germany.
Sebastian KreiterBioNTech, Mainz, Germany.
Heinrich HaasBioNTech, Mainz, Germany.
Sebastian AttigTRON, Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany.
Richard RaeTRON, Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany.
Katarina CukBioNTech, Mainz, Germany.
Alexandra Kemmer-BrückBioNTech, Mainz, Germany.
Andrea BreitkreuzBioNTech, Mainz, Germany.
Claudia TolliverBioNTech, Mainz, Germany.
Janina CasparBioNTech, Mainz, Germany.
Juliane QuinkhardtBioNTech, Mainz, Germany.
Lisa HebichBioNTech, Mainz, Germany.
Malte SteinBioNTech, Mainz, Germany.
Alexander HohbergerTRON, Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany.
Isabel VoglerBioNTech, Mainz, Germany.
Inga LiebigBioNTech, Mainz, Germany.
Stephanie RenkenBioNTech, Mainz, Germany.
Julian SikorskiBioNTech, Mainz, Germany.
Melanie LeiererDepartment of Dermatology and National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
Verena MüllerSkin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidrun Mitzel-RinkDepartment of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Matthias MiedererDepartment of Nuclear Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.ORCID http://orcid.org/0000-0001-5075-5995
Christoph HuberBioNTech, Mainz, Germany.
Stephan GrabbeDepartment of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Jochen UtikalSkin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Andreas PinterDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany.
Roland KaufmannDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany.
Jessica C Hassel *Department of Dermatology and National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
Carmen Loquai *Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Özlem Türeci *BioNTech, Mainz, Germany.
BioNTech (Germany) · DEJohannes Gutenberg University Mainz · DEGerman Cancer Research Center · DEGoethe University Frankfurt · DEHeidelberg University · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treating patients who have cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-refractory tumours
Indexed as
Antigens, NeoplasmAntineoplastic AgentsCancer VaccinesCombined Modality TherapyHumansMelanomaNeoplasm StagingProgrammed Cell Death 1 ReceptorRNA, NeoplasmT-LymphocytesT-Lymphocytes, CytotoxicVaccinationAntigens, NeoplasmAntineoplastic AgentsCancer VaccinesPDCD1 protein, humanProgrammed Cell Death 1 ReceptorRNA, Neoplasm
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.